To Compare Safety and Pharmacokinetic Properties of CJ-30039 and Lipidil Supra

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01501435
Recruitment Status : Completed
First Posted : December 29, 2011
Last Update Posted : January 2, 2017
Information provided by (Responsible Party):
CJ HealthCare Corporation

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : April 2012
  Actual Study Completion Date : June 2012